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ABSTRACT (word count = 299) 1 
Background: The APOE risk allele (ε4) is associated with higher total cholesterol 2 
(TC), amplified response to saturated fatty acid (SFA) reduction and increased CVD. 3 
While knowledge of gene ‘risk’ may enhance dietary change, it is unclear whether ε4 4 
carriers would benefit from gene-based personalized nutrition (PN).  5 
Objectives: The aims of this study were to investigate interactions between APOE 6 
genotype and (a) habitual dietary fat intake and (b) modulations of fat intake on 7 
metabolic outcomes; (c) determine whether gene-based PN results in greater dietary 8 
change compared with standard dietary advice (Level 0) and non-gene-based PN 9 
(Levels 1-2) and (d) assess the impact of knowledge of APOE risk (risk: E4+, non-10 
risk: E4-) on dietary change following gene-based PN (Level 3).  11 
Design: Individuals (n=1466) recruited into the Food4Me pan-European PN dietary 12 
intervention study were randomized to four treatment arms and genotyped for APOE 13 
(rs429358 and rs7412). Diet and dried blood spot TC and omega-3 index were 14 
determined at baseline and after 6-months intervention. Data were analyzed using 15 
adjusted general linear models. 16 
Results: Significantly higher TC concentrations were observed in E4+ participants 17 
compared with E4- (P <0.05). Although there were no significant differences in APOE 18 
response to gene-based PN (E4+ vs. E4-), both groups had a greater reduction in 19 
SFA (%TE) intake when compared with Level 0 (E4+, -0.72% vs. -1.95%, P =0.035; 20 
E4-, -0.31% vs. -1.68%, P =0.029). Gene-based PN was associated with a smaller 21 
reduction in SFA intake compared with non-gene-based PN (Level 2) for E4- 22 
participants (-1.68% vs. -2.56%, P =0.025).  23 
Conclusions: The APOE ε4 allele was associated with greater TC. Whilst gene-24 
based PN targeted to APOE was more effective in reducing SFA intake than 25 
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standard dietary advice, there was no difference between APOE ‘risk’ and ‘non-risk’ 26 
groups. Furthermore, disclosure of APOE ‘non-risk’ may have weakened dietary 27 
response to PN.    28 
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INTRODUCTION 29 
Coronary heart disease (CHD) is the leading cause of global mortality, 30 
accounting for 1 of 5 deaths in Europe (1). Recent estimates suggest that up to 80% 31 
of CHD and cerebrovascular disease could be avoided by improving diet and lifestyle 32 
(2). While intervention strategies have traditionally used a ‘one-size-fits-all’ approach 33 
to change dietary behaviour, recent evidence suggests that a personalized approach 34 
may be more effective (3, 4). Moreover, there has been much interest in the use of 35 
genetic information to tailor dietary advice, yet further RCTs are needed to establish 36 
the benefit of such advice on sustained dietary changes (5, 6). Of particular interest 37 
in relation to CHD risk is the APOE genotype. 38 
The APOE gene is a key regulator of cholesterol and lipid metabolism. APOE is 39 
polymorphic, with the common missense polymorphisms (rs429358 and rs7412) 40 
resulting in three alleles, ε2, ε3 and ε4, combining to form 6 haplotypes, E2/E2, 41 
E2/E3, E2/E4, E3/E3, E3/E4 and E4/E4. In a sample of 5805 Caucasians, the APOE 42 
allele frequency for ε2, ε3 and ε4 was 0.08, 0.77 and 0.15 respectively (7). The ε4 43 
allele is associated with increased serum total cholesterol (TC), low-density 44 
lipoprotein cholesterol (LDL-C) as well as coronary artery disease and mortality (8-45 
12). Estimates of the CHD hazard ratio for E4+ (E3/E4 and E4/E4), compared with 46 
E4- (E3/E3), range from 1.06 to 1.42 (8, 9, 11, 13). There is also a growing body of 47 
evidence showing that the APOE genotype may influence lipid response to dietary 48 
fat; data from intervention studies suggest that E4+ participants may be more 49 
sensitive to dietary cholesterol, total fat and, in particular, SFA modulation (14, 15). 50 
Given their predisposition to CHD, ε4 carriers might benefit from a lower dietary SFA 51 
and blood cholesterol (16) and gene-based PN intervention. However, there is a 52 
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concern that gene-based PN may reduce motivation for dietary change in individuals 53 
without ‘risky genes’ and undermine current healthy eating messages (17).  54 
The Food4Me study is a pan-European, 6-month, web-based RCT designed to 55 
assess the impact of personalizing dietary advice on change in dietary behaviour. 56 
Participants were allocated into one of four intervention groups based on standard 57 
guidelines (control), dietary intake (level 1), dietary intake and phenotype (level 2) 58 
and dietary intake, phenotype and genotype (level 3). Level 3 participants received 59 
feedback on four genes: MTHFR, FADS1, TCF7L2, FTO and APOE.   60 
The aim of the present analysis was to investigate interactions between APOE 61 
genotype and (a) habitual dietary fat intake and (b) modulations of fat intake on 62 
metabolic outcomes in the Food4Me study, (c) assess whether gene-based PN led to 63 
greater changes in diet compared with standard dietary advice (control) and non- 64 
gene-based PN for E4- and E4+ participants and (d) assess the impact of knowledge 65 
of APOE risk on changes in diet and metabolic outcomes following gene-based PN.  66 
 67 
PARTICIPANTS AND METHODS 68 
The Food4Me Proof-of-Principle (PoP) study is a 6-month randomized 69 
controlled dietary advice intervention study conducted in 7 European research 70 
centers: University College Dublin, Ireland, University of Reading, UK, Maastricht 71 
University, the Netherlands, University of Navarra, Spain, Harokopio University, 72 
Greece, National Food and Nutrition Institute, Poland, and Technische Universität 73 
München, Germany. The study had a parallel design with 4 intervention arms and 74 
was conducted via the web to emulate a web-delivered PN service 75 
(www.food4me.org) (18). Ethics approval was granted at each center and digital 76 
informed consent was obtained prior to participation. The study was registered at 77 
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clinicaltrials.gov (ref. NCT01530139) and was developed following international 78 
regulations and the Helsinki Declaration. 79 
Participants 80 
A total of 1,607 participants (aged ≥ 18 years) were recruited to the Food4Me 81 
study, as detailed elsewhere (19). Exclusion criteria were: no or limited access to the 82 
Internet, following a medically prescribed diet in the past 3 months, or presence of a 83 
condition likely to alter dietary requirements e.g. Crohn’s disease, coeliac disease, 84 
food allergy/intolerance, pregnancy or lactation.  85 
Study design 86 
A randomization scheme, incorporating both gender and age categories (< 45 87 
years and >45 years), was used to allocate participants to one of the four Food4Me 88 
intervention groups: Level 0: standard non-personalized dietary and physical activity 89 
(PA) advice; Level 1: advice based on dietary intake and PA; Level 2: advice based 90 
on dietary intake, PA and phenotype (blood biomarkers) and Level 3: advice based 91 
on dietary intake, PA, phenotype and genotype. Detailed recruitment and study 92 
procedures are reported elsewhere (19).   93 
Interaction with study participants was conducted remotely via the Food4Me 94 
website, by e-mail and post, using standardized operating procedures. A study 95 
welcome pack was sent to the participants via post containing: a dried blood spot 96 
(DBS) collection kit (Vitas Ltd, Oslo, Norway), an Isohelix SK-1 DNA buccal swab kit 97 
(LCG Genomics, Hertfordshire, UK), a TracmorD tri-axial accelerometer (Philips 98 
Consumer Lifestyle, The Netherlands; http://www.directlife.philips.com), measuring 99 
tape and standardized instructions for completion of baseline measurements (m0). 100 
On the allocated study day and following an 8-hour overnight fast, participants 101 
 The American Journal of Clinical Nutrition AJCN/2016/135012 Version 2
 9
collected DBS and buccal swab samples, and measured their height, weight and 102 
waist circumference (WC). Questionnaires to be completed on the same day 103 
included the validated Food4Me food frequency questionnaire (20, 21) and the 104 
validated Baecke physical activity questionnaire (22-24). Participants repeated these 105 
measurements, excluding the buccal cell sample, at 3 (m3) and 6 months (m6). The 106 
TracmorD tri-axial accelerometer (25) was worn for the entire duration of the study, 107 
and data were uploaded on a bi-weekly basis. 108 
Dietary feedback 109 
Following analysis of data collected at m0 and m3, participants received tailored 110 
dietary feedback (in their native language) according to their study allocation group. 111 
The dietary feedback provided was based on a pre-defined set of algorithms 112 
incorporating dietary, anthropometric, PA, phenotypic and genotypic data where 113 
appropriate. The system was designed to ensure consistent feedback across centres 114 
and has since been successfully automatized (26). APOE gene variants were coded 115 
as ‘risk’ (a genetic variation that can be modified by diet, i.e. E3/E4 or E4/E4 (E4+)) 116 
or ‘non-risk’ (E2/E2, E2/E3, E3/E3 (E4-)). Alongside the risk result, Level 3 117 
participants received the following basic information about the APOE genotype: “A 118 
specific variation of this gene is associated with a greater need to maintain healthy 119 
cholesterol levels. Decreasing saturated fat intake has been associated with an 120 
improvement in cholesterol and factors relating to cardiovascular health in these 121 
individuals.” For Level 3 E4+ participants with high dietary SFA intake and/or high 122 
blood TC, who were being advised to lower dietary SFA, reference to ‘gene risk’ was 123 
also included in the advice message, i.e. “You have a genetic variation that can 124 
benefit by keeping a healthy intake of saturated fat and a normal level of blood 125 
cholesterol.” 126 
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Biochemical analysis 127 
Participants were asked to complete 2 DBS cards each containing 5 blood 128 
spots, at m0, m3 and m6 (approximately150 μL blood per card). After drying the 129 
blood spots at room temperature for 2-4 hours, the cards were placed in a sealed 130 
aluminum bag (Whatman Foil Bags, item no. 10534321, Whatman Inc., Sanford, ME) 131 
containing a drying sachet (Sorb-it, item no. 10548234, Süd-Chemie, Germany) and 132 
posted back to the research center in their country. Researchers subsequently 133 
shipped the DBS cards to Vitas (Vitas Ltd, Norway) for analysis of whole blood TC 134 
(LC-UV) and omega-3 index [(eicosapentaenoic acid (EPA) + docosahexaenoic acid 135 
(DHA)/ total fatty acids) × 100] (27). Fatty acids were measured using GC-FID. 136 
DNA extraction and genotyping 137 
Participants were instructed to rub the Isohelix SK-1 DNA buccal swab against 138 
the inside of their cheek for one minute before returning it to a plastic tube containing 139 
an Isohelix Dri-capsule. Upon return to the center, swabs were shipped to LCG 140 
Genomics (LCG Genomics, Hertfordshire, UK) for genotypic analysis. Following DNA 141 
extraction, KASPTM genotyping assays were used to provide bi-allelic scoring of 142 
polymorphisms in the APOE gene (rs429358 and rs7412). Hardy-Weinberg 143 
equilibrium for multiple alleles was analyzed, no significant deviation was observed 144 
for rs7412 (0.91; P=1.00) whereas rs429358 displayed linkage disequilibrium (0.005; 145 
P=0.008). 146 
Statistical analyses 147 
Data are presented as means ± SEM. Data were checked for normality of 148 
distribution and skewed variables were normalised using Log10 (omega-3 index) and 149 
square root (TC) transformations. General linear models (GLM), adjusted for center, 150 
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gender, age and body mass index (BMI), were used to assess differences in baseline 151 
anthropometric and biochemical values between genotype groups. Habitual nutrient 152 
intake-gene interactions were assessed using the same GLM model but with the 153 
addition of a dietary fat × genotype interaction term; fat were dichotomised by median 154 
intake to assess the impact of the APOE genotype on TC and omega-3 index in 155 
participants with a similar habitual intake. Post-hoc Bonferroni tests were used to 156 
detect specific differences between groups. 157 
Interactions between genotype and dietary fat on TC and omega-3 index 158 
following dietary advice intervention were assessed using % change in dietary fat 159 
intake, with 0% used as a reference to dichotomize participants (i.e. reduction vs. 160 
increase in fat intake), and then using the resulting groups as fixed factors in the 161 
GLM. The interaction term genotype × change in fat was then added to the GLM, 162 
with the change in biomarker as the response variable and the respective pre-163 
intervention/ baseline biomarker value as a covariate. The model was adjusted for 164 
baseline variables, age, gender, center and weight change [post intervention weight 165 
(kg) – pre intervention weight (kg)]. 166 
The impact of knowledge of APOE risk (risk: E4+, E3E4 and E4/E4; and non-167 
risk: E4-, E2/E2, E2/E3 and E3/E3) on change in diet and TC and omega-3 index 168 
(m6-m0) for Level 3 participants advised to lower their SFA at baseline (with high 169 
dietary SFA and/or high blood TC) were assessed using GLM. Models were adjusted 170 
for baseline variables, age, gender, center and weight change. To assess whether 171 
gene-based PN led to greater changes in diet, TC and omega-3 index (m6-m0) than 172 
standard dietary advice (Level 0) and non gene-based PN (Levels 1-2), a contrast 173 
analysis was performed. Separate analyses were conducted for E4+ (risk) and E4- 174 
(non-risk) with Level 3 as the reference group and Levels 0, 1 and 2 as the 175 
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comparison groups. As previously, participants with high dietary SFA and/or high 176 
blood TC who were advised to lower their SFA at baseline were included and 177 
analyses were adjusted for baseline variables, age, gender, center and weight 178 
change. Statistical analyses were performed using STATA (version 13.0, StataCorp, 179 
TX, USA). 180 
 181 
RESULTS 182 
Subject characteristics 183 
A total of 1466 of the 1607 participants randomized into the Food4Me study 184 
were genotyped for APOE and included in the baseline analysis. Frequency of APOE 185 
genotype and APOE allele according to Food4Me country are presented in Table 1. 186 
APOE E2/E4 participants (n=27) were removed from subsequent analysis due to 187 
their low population frequency. Subject characteristics including anthropometry and 188 
fasted biomarkers are presented according to APOE genotype in Table 2. There was 189 
no evidence of a genotype-dependant difference in baseline anthropometry, although 190 
E4+ participants had higher TC than E4- (P = 0.040 for E3/E3 and P = 0.002 for E2 191 
carriers).  192 
Habitual dietary and genotype effects at baseline 193 
The associations between dietary fat (total fat, SFA, monounsaturated fatty 194 
acids (MUFA), polyunsaturated fatty acids (PUFA) and omega-3), APOE genotype, 195 
dietary fat × genotype interactions and TC and omega-3 index, are reported in Table 196 
3. Dietary intake was dichotomized at the median (total fat, 35.8%; SFA, 14.0%; 197 
MUFA, 13.5%; PUFA, 5.6; omega-3, 0.67%) to determine the effect of specific 198 
 The American Journal of Clinical Nutrition AJCN/2016/135012 Version 2
 13
genotypes in participants with similar habitual dietary fat intakes; presented in Table 199 
3 according to genotype group. 200 
An independent effect of genotype was observed for dietary fat and TC 201 
concentrations at baseline (total fat, P= 0.002; SFA, P= 0.002; MUFA, P= 0.002; 202 
PUFA, P= 0.003 and omega-3, P= 0.004), with the highest TC concentrations seen in 203 
carriers of ε4 allele (E4+). Overall diet effects (SFA, P= 0.008; MUFA, P= 0.025; 204 
PUFA, P= 0.007 and omega-3, P< 0.001) were observed for omega-3 index, with 205 
lower dietary SFA (11.7% ± 0.1) and higher PUFA (6.80% ± 0.05) and omega-3 206 
(0.89% ± 0.01) fat intake associated with a higher omega-3 index. Although a 207 
significant MUFA × APOE interaction was observed for omega-3 index (P = 0.025), 208 
no differences between genotype groups and fat intakes were observed following 209 
post-hoc analyses. 210 
Dietary and genotype effects of intervention (irrespective of group allocation) 211 
The associations between change in dietary fat intake (total fat, SFA, MUFA, 212 
PUFA and omega-3), APOE genotype and change in fat × APOE interactions on TC 213 
and omega-3 index following intervention (m6-m0) are reported in Table 4. Dietary 214 
intake was split into participants who reduced fat intake and those who increased fat 215 
intake. Mean reductions and increases in dietary fat intakes are presented according 216 
to genotype group.  217 
There was a significant impact of genotype on change in TC concentrations 218 
following dietary advice intervention (total fat, P= 0.016; SFA, P= 0.025; MUFA, P= 219 
0.019; PUFA, P= 0.024 and omega-3, P= 0.027). There were no independent effects 220 
of diet on lipid biomarkers following dietary advice intervention, although trends were 221 
observed for change in PUFA (P= 0.068) and omega-3 fat intakes (P= 0.087) on 222 
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omega-3 index. A trend was also observed for an omega-3 fat intake × APOE 223 
interaction on omega-3 index (P= 0.087).  224 
Effect of knowledge of APOE gene risk on dietary change compared with other 225 
levels of personalization 226 
 The allocation of APOE risk according to intervention level is shown in Figure 227 
1. Participants (levels 1-3) advised to lower dietary SFA at baseline were selected for 228 
subsequent analysis. The effects of knowledge of APOE risk (E4+) in participants 229 
advised to reduce SFA intake at baseline on changes in diet, TC and omega-3 index 230 
(m6-m0) compared with other levels of personalization are reported in Table 5 A 231 
significantly greater reduction in total fat and SFA (%TE) was observed in E4+ 232 
participants receiving gene-based PN (Level 3) compared to those in the control 233 
group (P =0.034 and P =0.035 respectively). However, there were no differences in 234 
change in diet or biomarkers between personalized intervention groups.
 
235 
The effects of knowledge of APOE non-risk (E4-) in participants advised to 236 
reduce SFA intake at baseline on changes in diet, TC and omega-3 index (m6-m0) 237 
compared with other levels of personalization are reported in Table 6. As previously, 238 
participants receiving gene-based PN had a significantly greater reduction in dietary 239 
SFA (%TE) compared with those in the control group (P =0.029). For total fat (%FE), 240 
a slight increase in intake was observed for the control group (Level 0) compared 241 
with a reduction in Level 3 (difference 2.72% TE, P =0.006). The opposite was 242 
observed for total carbohydrate, which reduced in the control group (Level 0) and 243 
increased in Level 3 (difference 2.15 %TE, P =0.027). 244 
When comparing levels of personalization, a 0.88% greater reduction in SFA 245 
(%TE) was observed in E4- participants receiving non-gene-based PN (Level 2; PN 246 
based on diet and phenotype) compared with those E4- participants receiving gene-247 
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based PN (P = 0.025). There were no significant differences between change in total 248 
fat, PUFA, MUFA, omega-3, carbohydrate and protein intake, or TC and omega-3 249 
index for E4- carriers according to whether they received gene-based or non-gene-250 
based PN (L3 vs. L1-2). 251 
Effect of knowledge of APOE genotype on dietary change following gene-252 
based personalized advice PN  253 
The effect of knowledge of APOE risk (risk: E4+, E3/E4 and E4/E4 and non-254 
risk: E4-, E2/E2, E2/E3 and E3/E3) in participants advised to reduce SFA intake at 255 
baseline on changes in diet, TC and omega-3 index (m6-m0) following gene-based 256 
PN (L3) are reported in Table 7. Approximately 30% of E4- participants receiving 257 
gene-based PN were advised to lower their SFA intake at baseline, compared with 258 
53% of E4+ carriers (Figure 1). Following intervention, there were no significant 259 
differences in dietary response or change in biomarker between E4+ and E4- 260 
participants. 261 
 262 
DISCUSSION 263 
Key findings in the present analysis were higher TC concentrations in E4 264 
carriers (E4+) and a nutrient intake-gene interaction between APOE genotype and 265 
MUFA intake for omega-3 index at baseline. Following intervention, gene-based PN 266 
resulted in sigificantly greater reductions in total fat and SFA (%TE) compared with 267 
standard dietary advice (control), irrespective of gene risk. For E4- (‘non-risk’) 268 
participants advised to lower SFA intake, gene-based PN resulted in smaller changes 269 
in dietary SFA intake at month 6 than non-gene-based PN (Level 2). 270 
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Although the APOE rs429358 distribution was not in Hardy-Weinberg 271 
equilibrium, the haplotype frequencies observed in the Food4Me cohort (ε2, 6.5; ε3, 272 
79.3; ε4, 14.2) were similar to those reported in previous studies of European 273 
populations (28). In contrast to previous observations (29, 30), there was no clear 274 
geographical cline in ε4 frequency.  275 
DBS TC differed according to APOE genotype with significantly higher TC 276 
observed in E4+ participants compared with E4-. The difference in TC between E4+ 277 
and those who were E4-: E3/E3 in the present study (0.15 mmol/L) was similar to 278 
previous data (0.16-0.36 mmol/L) in a large meta-analysis of 54,377 participants (31).  279 
At baseline, there was a significant nutrient intake-gene interaction between 280 
total MUFA intake and APOE on long-chain omega-3 index, a reliable biomarker of 281 
omega-3 status, and dietary omega-3 PUFA, EPA and DHA intake (32, 33). 282 
Furthermore, there is a dose-dependent inverse association between omega-3 index 283 
and CHD mortality (33), with an index ≥ 8% offering the most cardio-protective 284 
effects and an index ≤ 4% being associated with the greatest risk of CHD mortality 285 
(27). Thus, the omega-3 index may be a risk factor for CHD (34). In the Food4Me 286 
study, a higher omega-3 index was associated with lower SFA and higher PUFA and 287 
dietary omega-3 intake. In a study investigating the determinants of omega-3 index in 288 
a Mediterranean population, there were significant associations between EPA and 289 
DHA intakes and omega-3 index (P< 0.001) and a trend for an inverse association 290 
between dietary SFA and omega-3 index (P= 0.095) (35).  291 
It has been suggested that gene-based dietary information is more 292 
understandable and useful than general dietary guidelines (36) and may enhance 293 
motivation to change (37). In a 2010 systematic review, a beneficial effect of 294 
genome-based risk estimates on dietary behavior was reported (pooled OR for 2 295 
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RCT 2.24, 95% CI 1.17 to 4.27, P = 0.01, I2 = 0%); but no benefit of genome-based 296 
risk estimates on intention to change dietary behavior was observed (5). 297 
Furthermore, in a Canadian RCT, knowledge of ACE gene risk resulted in a 298 
significantly greater reduction in sodium intake compared with non-gene based 299 
advice (-287 ± 114 vs. 130 ± 118 mg/day, P = 0.008) at 12-month follow-up (38). 300 
Change in sodium intake by participants carrying the ‘non-risk’ ACE genotype (-244 301 
mg/day) was not significantly different (P = 0.11) compared with the control group. In 302 
our present study, gene-based PN promoted significantly greater reductions in the 303 
intake of total fat and SFA than standard dietary advice (control), for both risk (E4+) 304 
and non-risk (E4-) participants advised to lower SFA. However, there were no 305 
significant differences in change of diet, TC or omega-3 index between APOE risk 306 
groups (E4+ and E4-) receiving gene-based PN. In the REVEAL study, which 307 
investigated the impact of knowledge of Alzheimer’s disease (AD) risk (estimated 308 
using APOE genotype and family history to generate a numerical risk) on dietary 309 
behaviors, E4+ participants were significantly more likely to endorse AD-specific 310 
health behavior change than E4- participants at 12 months follow-up (39). A similar 311 
result was observed in a study investigating the impact of knowledge of FTO 312 
genotype on readiness to control weight; whereby individuals with higher ‘risk’ (AA or 313 
AT) displayed greater willingness to change than those with lower risk (TT) (P = 314 
0.051) (40).  315 
Whilst there was no additional benefit of gene-based PN for E4+ participants in 316 
the Food4Me study, knowledge of ‘non-risk’ (E4-) resulted in a lower reduction in 317 
SFA intake at 6 months compared with E4- participants receiving non-gene-based 318 
PN (Level 2) who were not informed of their APOE risk (-1.68% vs. -2.56%). 319 
Providing ‘no-risk’ genotypic results may reduce motivation to follow dietary advice 320 
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(41). A potential reason for the lack of response in Food4Me E4 carriers is the 321 
absence of a specific behavior change technique (BCT) involving information on the 322 
consequences of a specific behavior related to genotype. A key BCT in the CALO-RE 323 
taxonomy (a 40-item taxonomy to improve PA and healthy eating behaviors) is to 324 
“provide information of the consequences of the behavior to the individual”. In the 325 
context of APOE genotype, a consequence of carrying the ε4 allele would be 326 
increased CVD risk (31) and the corresponding risk-reducing behavior would be 327 
lowering SFA intake.  In the present study, APOE risk information conveyed to 328 
participants was framed positively viz : “you have a genetic variation that can benefit 329 
by keeping a healthy intake of saturated fat and a normal level of blood cholesterol.” 330 
The lack of an explicit link to an adverse consequence of E4+ status, e.g. higher 331 
CVD risk, may have reduced the efficacy of this advice. In the REVEAL study, 332 
participants were informed that the E4 allele was associated with an increased risk of 333 
Alzheimer’s disease prior to gene disclosure (39). Whilst genotypic testing for 334 
polygenic disease risk may result in a fatalistic attitude (37), information on 335 
consequences of personal characteristics (e.g. genotype) and fear arousal can be 336 
useful aids in enhancing behavior change (42). In a meta-analysis of fear arousal 337 
techniques, stronger fear messages promoted greater intention and behavior change 338 
in public health campaigns, provided that the threat was perceived to be severe, 339 
personally relevant, and that the individual could take specific action to mitigate their 340 
risk (43). In a Finnish RCT, knowledge of personal APOE risk resulted in greater 341 
short-term improvements in dietary quality, WC and serum triacylglycerol, when 342 
participants were informed of the link between dietary fat, cholesterol and CVD risk in 343 
an oral communication session (44). Furthermore, E4+ individuals significantly 344 
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improved fat quality at 6-months (P <0.01), whereas there was no difference in fat 345 
quality in the E4- or control groups (44). 346 
A limitation of internet-delivered PN (as used in our Food4Me study) is the 347 
reduced opportunity to employ BCT in response to verbal and non-verbal cues (e.g. 348 
body-language, facial expressions). Recent focus group data also revealed a lack of 349 
understanding amongst consumers of the use of genetic information to tailor dietary 350 
advice, and opinions regarding gene-based PN were mostly negative (45). Given that 351 
understanding and ‘knowledge’ of specific gene-based PN advice was not evaluated 352 
in the Food4Me study, it is not possible to ascertain if this contributed to the lack of 353 
effect observed. The Food4Me study was designed to assess the impact of three 354 
levels of personalization on dietary change and was not specifically targeted to the 355 
APOE genotype. Furthermore, although participants were informed that they had a 356 
‘risky’ gene variant that would benefit from dietary change, advice was not stratified 357 
according to specific genotype groups (e.g. differing advice for E2/E3 and E3/E3).  358 
Strengths of this study include using the internet to assess and deliver dietary advice, 359 
prospective genotyping, a larger sample size than reported previously (39, 44, 46), 360 
the measurement of actual dietary change, as distinct from intention to change, and 361 
the availability of relevant blood-based biomarkers of fat status (obtained from 362 
unsupervised sampling). As such, the Food4Me study provides robust evidence of 363 
the impact of knowledge of APOE risk on adherence to dietary advice. 364 
 365 
CONCLUSION 366 
APOE status was significantly associated with TC at baseline with highest 367 
concentrations in E4+ participants. Whilst gene-based PN targeted to APOE was 368 
more effective in reducing SFA intake than standard dietary advice, there was no 369 
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added benefit of knowledge of APOE ‘risk’ on dietary change. Furthermore, it 370 
appears that disclosure of genotypic ‘non-risk’ status may have weakened the dietary 371 
response to PN. Future research should explore ways in which this detrimental 372 
response to gene-based PN can be mitigated.   373 
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TABLE 1. Frequency of APOE genotype and APOE allele by Food4Me center (n=1466) 
 All Ireland UK The Netherlands Germany Poland Spain Greece 
Genotype (n, 
%)         
E2/E2 6 (0.4) 1 (0.5) 0 (0.0) 3 (1.4) 0 (0.0) 2 (1.0) 0 (0.0) 0 (0.0) 
E2/E3 152 (10.4) 14 (6.5) 22 (10.6) 28 (12.7) 21 (10.2) 29 (14.4) 22 (10.4) 16 (7.7) 
E2/E4 27 (1.8) 3 (1.4) 6 (2.9) 3 (1.4) 7 (3.4) 4 (2.0) 1 (0.5) 3 (1.4) 
E3/E3 922 (62.9) 133 (62.1) 132 (64.1) 124 (56.4) 125 (61.0) 125 (62.1) 139 (65.6) 144 (69.2) 
E3/E4 330 (22.5) 57 (26.6) 43 (20.8) 58 (26.4) 48 (23.4) 38 (18.9) 46 (21.7) 40 (19.2) 
E4/E4 29 (2.0) 6 (2.8) 3 (1.5) 4 (1.8) 4 (2.0) 3 (1.5) 4 (1.9) 5 (2.4) 
Total 1466 (100) 214 (100) 206 (100) 220 (100) 205 (100) 201 (100) 212 (100) 208 (100) 
E2 carriers1 158 (10.8) 15 (7.0) 22 (10.7) 31 (14.1) 21 (10.2) 31 (15.4) 22 (10.4) 16 (7.7) 
E4 carriers1 359 (24.5) 63 (29.4) 46 (22.3) 62 (28.2) 52 (25.4) 41 (20.4) 50 (23.6) 45 (21.6) 
         
Allele frequency 
(%)         
ε2 6.5 4.4 6.5 8.4 6.8 8.9 5.4 4.6 
ε3 79.3 78.7 76.2 75.9 77.8 76.0 81.6 82.7 
ε4 14.2 16.8 17.4 15.7 15.3 15.1 13.0 12.7 
1Genotype groups combined; E2 carriers represent E2/E2 and E2/E3, E4 carriers represent E4/E3 and E4/E4                                                                            
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TABLE 2. Anthropometric characteristics and fasted blood biomarkers by APOE genotype in European adults in the Food4Me study1 
  
 APOE genotype1    
  E4-  E4+  
 
 
All (n=1439) E2 carriers (n=158) E3/E3 (n=922)  E4 carriers (n=359) P2 
Gender ratio (M/F) 611/846      
Age (y) 40 ± 0.4 40 ± 1 40 ± 0.4  40 ± 0.7 0.630 
BMI (kg/m2) 25.5 ± 0.13 25.7 ± 0.4 25.4 ± 0.2  25.5 ± 0.3 0.704 
Weight (kg) 74.6 ± 0.44 76.8 ± 1.4 74.3 ± 0.5  75.4 ± 0.8 0.608 
Waist circumference (m) 0.86 ± 0.004 0.87 ± 0.01 0.86 ± 0.005  0.85 ± 0.01 0.693 
Height (m) 1.71 ± 0.003 1.73 ± 0.01 1.71 ± 0.003  1.72 ± 0.005 0.252 
       
Cholesterol (mmol/L) 4.59 ± 0.03 4.42 ± 0.08a 4.55 ± 0.03a  4.70 ± 0.05b 0.002 
Omega 3 index 5.68 ± 0.03 5.81 ± 0.10 5.66 ± 0.04  5.74 ± 0.06 0.341 
1
 Data are means ± SEM 
2 Data were analyzed by GLM with adjustment for age, gender, center and BMI. Where P for genotype < 0.05, a Bonferroni post-hoc test 
was applied to determine between-group effects. Superscript letters a and b denote significant differences between genotype groups, P < 
0.05. 
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TABLE 3. Effect of APOE genotype and dietary fat intake (total and fat classes)1 on metabolic markers measured in dried blood spots at 
baseline in the Food4Me intervention study2 
 E4-  E4+  
 E2 carriers (n=158) E3/E3 (n=922)  E4 carriers (n=359) P3 
 Low Intake High Intake Low Intake High Intake  Low Intake High Intake Diet Genotype Diet × Genotype 
Total fat  (n=80) (n=78) (n=452) (n=470)  (n=188) (n=171)    
   Total fat (%TE) 31.7 ± 0.4 39.9 ± 0.4 31.3 ± 0.2 40.6 ± 0.2  31.3 ± 0.3 40.6 ± 0.3    
  Cholesterol (mmol/L) 4.37 ± 0.11 4.48 ± 0.11 4.45 ± 0.04 4.64 ± 0.04  4.66 ± 0.07 4.73 ± 0.07 0.251 0.002 0.435 
   Omega-3 index 5.81 ± 0.10  5.81 ± 0.13 5.66 ± 0.06 5.64 ± 0.06  5.79 ± 0.09 5.68 ± 0.09 0.989 0.344 0.456 
SFA (n=77) (n=81) (n=456) (n=466)  (n=187) (n=172)    
   SFA (%TE) 11.7 ± 0.2  16.7 ± 0.2 11.7 ± 0.1 16.7 ± 0.1  11.6 ± 0.1 16.4 ± 0.1    
  Cholesterol (mmol/L) 4.40 ± 0.11 4.44 ± 0.11 4.49 ± 0.04 4.61 ± 0.04  4.66 ± 0.07 4.73 ± 0.07 0.413 0.002 0.789 
   Omega-3 index 5.86 ± 0.14 5.76 ± 0.13 5.72 ± 0.06 5.58 ± 0.06  5.88 ± 0.09 5.57 ± 0.09 0.008 0.343 0.573 
MUFA  (n=84) (n=74) (n=451) (n=471)  (n=185) (n=174)    
  MUFA (%TE) 11.7 ± 0.2 15.5 ± 0.2  11.4 ± 0.1 16.1 ± 0.1  11.5 ± 0.1 16.1 ± 0.2    
  Cholesterol (mmol/L) 4.40 ± 0.10 4.45 ± 0.11 4.49 ± 0.04 4.60 ± 0.04  4.98 ± 0.07 4.80 ± 0.07 0.078 0.002 0.470 
  Omega-3 index 5.67 ± 0.13 5.97 ± 0.14 5.71 ± 0.06 5.60 ± 0.06  5.86 ± 0.09 5.60 ± 0.09 0.025 0.280 0.025 
PUFA  (n=86) (n=72) (n=460) (n=462)  (n=174) (n=185)    
   PUFA (%TE) 4.7 ± 0.1 6.8 ± 0.1 4.6 ± 0.1 6.8 ± 0.1  4.7 ± 0.1 6.7 ± 0.1    
  Cholesterol (mmol/L) 4.38 ± 0.10 4.47 ± 0.11 4.51 ± 0.04 4.59 ± 0.04  4.69 ± 0.07 4.69 ± 0.07 0.445 0.003 0.614 
   Omega-3 index 5.65 ± 0.13 6.00 ± 0.14 5.52 ± 0.06 5.77 ± 0.06  5.62 ± 0.09 5.84 ± 0.09 0.007 0.291 0.803 
Omega-3  (n=80) (n=78) (n=485) (n=437)  (n=155) (n=204)    
   Omega-3 (%TE) 0.55 ± 0.01 0.90 ± 0.03 0.55 ± 0.01 0.89 ± 0.01  0.55 ± 0.01 0.89 ± 0.02    
  Cholesterol (mmol/L) 4.43 ± 0.11 4.41 ± 0.11 4.50 ± 0.04 4.61 ± 0.05  4.64 ± 0.08 4.74 ± 0.07 0.068 0.004 0.820 
   Omega-3 index 5.50 ± 0.13 6.12 ± 0.08 5.34 ± 0.05 5.99 ± 0.06  5.30 ± 0.09 6.07  ± 0.08 <0.001 0.546 0.463 
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1
 Intakes of fat were dichotomised at the median: total fat, 35.8% (low intake, 31.4% ± 0.1; high intake 40.5% ± 0.1); SFA, 14.0% (low intake, 
11.7% ± 0.1; high intake 16.6% ± 0.1); MUFA, 13.5% (low intake, 11.5% ± 0.1; high intake 16.0% ± 0.1); PUFA, 5.6% (low intake, 4.67% ± 0.02; 
high intake 6.80% ± 0.05); omega-3, 0.67% (low intake, 0.55% ± 0.01; high intake 0.89% ± 0.01) 
2
 Genotype groups combined; E2 carriers represent E2/E2 and E2/E3, E4 carriers represent E4/3 and E4/E4; %TE, % total energy; low intake, 
less than median fat intake; high intake, greater than median fat intake; data are mean ± SEM                                                                   
3
 Data were analysed by GLM with adjustment for centre, gender, age and BMI. Where P for diet x genotype < 0.05, a Bonferroni post-hoc test 
was applied to determine between-group effects (significant differences were not detected post-hoc) 
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TABLE 4. Effect of APOE genotype and change in dietary fat intake (total and fat classes)1 on changes in metabolic markers measured in dried 
blood spots between baseline and month 6 for participants in the Food4Me intervention study2 
 E4-  E4+  
 E2 carriers (n=132) E3/E3 (n=794)  E4 carriers (n=315) P3 
 
Decreased 
Intake 
Increased 
Intake 
Decreased 
Intake 
Increased 
Intake 
 Decreased 
Intake 
Increased 
Intake Diet Genotype 
Diet × 
Genotype 
Total fat (n=72) (n=60) (n=424) (n=370)  (n=178) (n=137)    
  Total fat (%TE) 
-4.49 ± 0.42 3.90 ± 0.41 -4.91 ± 0.19 3.93 ± 0.18  -4.76 ± 0.29 4.16 ± 0.34    
  Cholesterol 
(mmol/L) -0.26 ± 0.12 -0.24 ± 0.13 -0.18 ± 0.05 -0.21 ± 0.05 
 
-0.26 ± 0.08 -0.03 ± 0.09 0.527 0.016 0.313 
  Omega-3 index 0.24 ± 0.15 -0.08 ± 0.16 0.26 ± 0.06 0.25 ± 0.06  0.40 ± 0.09 0.15 ± 0.11 0.808 0.136 0.384 
SFA (n=86) (n=46) (n=484) (n=310)  (n=206) (n=109)    
  SFA (%TE) 
-2.56 ± 0.21 2.01 ± 0.23 -2.68 ± 0.10 1.75 ± 0.08  -2.48 ± 0.14 2.13 ± 0.19    
  Cholesterol 
(mmol/L) -0.32 ± 0.11 -0.14 ± 0.14 -0.21 ±0.05 -0.17 ± 0.06 
 
-0.18 ± 0.07 -0.11 ± 0.10 0.982 0.025 0.941 
  Omega-3 index 0.24 ± 0.14 -0.14 ± 0.17 0.33 ± 0.06 0.14 ± 0.07  0.39 ± 0.09 0.10 ± 0.12 0.986 0.069 0.377 
MUFA (n=64) (n=68) (n=397) (n=397)  (n=165) (n=150)    
  MUFA (%TE) 
-1.88 ± 0.18 1.65 ± 0.17 -2.10 ± 0.10 2.00 ± 0.10  -2.19 ± 0.15 2.13 ± 0.17    
  Cholesterol 
(mmol/L) -0.29 ± 0.13 -0.21 ± 0.12 -0.21 ± 0.05 -0.19 ± 0.05 
 
-0.29 ± 0.08 -0.01 ± 0.08 0.392 0.019 0.583 
  Omega-3 index 0.25 ± 0.15 -0.04 ± 0.15 0.23 ± 0.06 0.28 ± 0.06  0.36 ± 0.10 0.21 ± 0.10 0.547 0.309 0.373 
PUFA (n=58) (n=74) (n=357) (n=437)  (n=153) (n=162)    
  PUFA (%TE) -0.83 ± 0.10 1.12 ± 0.11 -1.06 ± 0.06 1.13 ± 0.06  -0.93 ± 0.07 1.13 ± 0.09    
  Cholesterol 
(mmol/L) -0.28 ± 0.13 -0.23 ± 0.12 -0.12 ± 0.05 -0.26 ± 0.05 
 
-0.23 ± 0.08 -0.09 ± 0.08 0.611 0.024 0.148 
  Omega-3 index 
-0.004 ± 0.16 0.18 ± 0.14 0.18 ± 0.07 0.32 ± 0.06  0.41 ± 0.10 0.17 ± 0.10 0.068 0.467 0.303 
Omega-3 (n=53) (n=79) (n=294) (n=500)  (n=129) (n=186)    
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  Omega-3 (%TE) 
-0.12 ± 0.02 0.18 ± 0.02 -0.14 ± 0.01 0.22 ± 0.02  -0.13 ± 0.01 0.15 ± 0.03    
  Cholesterol 
(mmol/L) -0.15 ± 0.14 -0.32 ± 0.11 -0.23 ± 0.06 -0.18 ± 0.05 
 
-0.18 ± 0.09 -0.14 ± 0.08 0.738 0.027 0.738 
  Omega-3 index 0.02 ± 0.17 0.14 ± 0.14 0.02 ± 0.07 0.39 ± 0.06  0.24 ± 0.11 0.32 ± 0.09 0.087 0.412 0.087 
1
 0% change in fat intake used as a reference to dichotomize participants i.e. comparison of reduction vs. increase in fat intake; total fat 
(decrease, -4.82% ± 0.15; increase 3.98% ± 0.15), SFA (decrease, -2.62% ± 0.08; increase 1.84% ± 0.08), MUFA (decrease, -2.10% ± 0.07; 
increase 1.99% ± 0.08), PUFA (decrease, -1.00% ± 0.04; increase 1.13% ± 0.04), omega-3 (decrease, -0.14% ± 0.01; increase 0.22% ± 0.02) 
2
 Genotype groups combined; E2 carriers represent E2/E2 and E2/E3, E4 carriers represent E4/3 and E4/E4; %TE, % total energy; increased 
intake, greater than 0% change in fat intake; decreased intake, less than 0% change in fat intake; data are mean change ± SEM (m6 - m0)                              
3
 Data were analysed by GLM with adjustment for baseline values, centre, gender, age and change in weight (m6 - m0).  
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TABLE 5. Effect of knowledge of APOE risk (E4+) on change in dietary intake between baseline and month 6 for participants in the Food4Me 
intervention study1 
 Control  Personalized intervention arms  P2 
Level 0 (L0) 
APOE risk 
(n=77) 
 Level 1 (L1) 
APOE risk 
(n=47) 
Level 2 (L2) 
APOE risk 
(n=35) 
Level 3 (L3) 
APOE risk 
 (n=40) 
 L3 vs. 
Control 
(L0) 
L3 vs. 
L1 
L3 vs.  
L2 
Total fat (%TE) 0.37 ± 0.65  -3.03 ± 0.79 -1.63 ± 1.00 -3.07 ± 0.86  0.034 0.970 0.317 
SFA (%TE) -0.72 ± 0.35  -2.53 ± 0.37 -1.58 ± 0.56 -1.95 ± 0.45  0.035 0.335 0.537 
MUFA (%TE) 0.37 ± 0.32  -0.71 ± 0.35 -0.41 ± 0.42 -1.05 ± 0.36  0.073 0.467 0.303 
PUFA (%TE) -0.04 ± 0.13  0.20 ± 0.19 0.30 ± 0.23 0.01 ± 0.23  0.718 0.965 0.720 
Omega-3 (%TE) 0.04 ± 0.03  0.08 ± 0.03 0.08 ± 0.03 0.08 ± 0.03  0.899 0.900 0.990 
Carbohydrate (%TE) -0.89 ± 0.76  1.89 ± 0.85 0.11 ± 0.98 1.55 ± 0.92  0.127 0.945 0.130 
Protein (%TE) 0.38 ± 0.43  0.40 ± 0.43 0.49 ± 0.49 1.37 ± 0.40  0.392 0.245 0.226 
          
BMI (kg/m2) -0.25 ± 0.13  -0.35 ± 0.15 -0.04 ± 0.19 -0.44 ± 0.18  0.231 0.590 0.086 
Cholesterol (mmol/L) -0.32 ± 0.11  -0.04 ± 0.16 -0.39 ± 0.15 -0.19 ± 0.16  0.240 0.663 0.228 
Omega-3 index -0.04 ± 0.11  0.29 ± 0.16 0.38 ± 0.16 0.14  ± 0.16  0.545 0.610 0.240 
1
 E4-, E2/E2, E2/E3 and E3/E3; E4+, E3/E4 and E4/E4; %TE, % total energy; data are mean change ± SEM (m6 - m0)  
2
 Data were analysed by GLM with adjustment for baseline values, centre, gender, age and change in weight (m6 - m0).  
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TABLE 6. Effect of knowledge of APOE non-risk (E4-) on change in dietary intake between baseline and month 6 for participants in the 
Food4Me intervention study1 
 Control  Personalized intervention arms  P2 
Level 0 (L0) 
APOE non-risk 
(n=225) 
 Level 1 (L1) 
APOE non-risk 
(n=145) 
Level 2 (L2) 
APOE non-risk 
(n=119) 
Level 3 (L3) 
APOE non-risk 
 (n=72) 
 L3 vs. 
Control 
(L0) 
L3 vs. 
L1 
 
L3 vs.  
L2 
Total fat (%TE) 0.31 ± 0.37  -2.63 ± 0.47 -3.42 ± 0.51 -2.41 ± 0.66  0.006 0.280 0.381 
SFA (%TE) -0.31 ± 0.20  -1.88 ± 0.25 -2.56 ± 0.27 -1.68 ± 0.35  0.029 0.119 0.025 
MUFA (%TE) 0.32 ± 0.17  -0.75 ± 0.22 -0.87 ± 0.24 -0.64 ± 0.31  0.012 0.382 0.601 
PUFA (%TE) 0.25 ± 0.11  -0.01 ± 014 0.04 ± 0.15 -0.18 ± 0.19  0.053 0.273 0.119 
Omega-3 (%TE) 0.13 ± 0.03  0.02 ± 0.04 0.05 ± 0.05 0.06 ± 0.06  0.278 0.442 0.903 
Carbohydrate (%TE) -1.22 ± 0.45  1.65 ± 0.55 1.92 ± 0.61 0.93 ± 0.79  0.027 0.211 0.558 
Protein (%TE) 0.85 ± 0.21  0.77 ± 0.26 0.80 ± 0.28 1.17 ± 0.36  0.997 0.346 0.634 
          
BMI (kg/m2) -0.28 ± 0.08  -0.44 ± 0.09 -0.41 ± 0.10 -0.51 ± 0.13  0.970 0.711 0.364 
Cholesterol (mmol/L) -0.27 ± 0.07  -0.22 ± 0.08 -0.39 ± 0.09 -0.41 ± 0.12  0.855 0.959 0.560 
Omega-3 index 0.27 ± 0.07  0.11 ± 0.09 0.26 ± 0.09 0.18 ± 0.12  0.536 0.700 0.464 
1
 E4-, E2/E2, E2/E3 and E3/E3; E4+, E3/E4 and E4/E4; %TE, % total energy; data are mean change ± SEM (m6 - m0)  
2
 Data were analysed by GLM with adjustment for baseline values, centre, gender, age and change in weight (m6 - m0).  
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TABLE 7. Effect of knowledge of APOE genotype on change in dietary intake between baseline and month 6 for participants receiving gene-
based personalized nutrition (Level 3) in the Food4Me intervention study1 
 Level 3 (L3) P2 
APOE non-risk (E4-) 
(n=72) 
APOE risk (E4+) 
(n=40) 
Total fat (%TE) -2.41 ± 0.64 -3.07  ± 0.86 0.433 
SFA (%TE) -1.68 ± 0.33 -1.95 ± 0.45 0.348 
MUFA (%TE) -0.64 ± 0.28 -1.05 ± 0.36 0.307 
PUFA (%TE) -0.18 ± 0.17 0.01 ± 0.23 0.223 
Omega-3 (%TE) 0.06 ± 0.02 0.08 ± 0.03 0.392 
Carbohydrate (%TE) 0.93 ± 0.68 1.55 ± 0.92 0.421 
Protein (%TE) 1.17 ± 0.30 1.37 ± 0.40 0.502 
    
BMI (kg/m2) -0.51 ± 0.13 -0.44 ± 0.18 0.229 
Cholesterol (mmol/L) -0.41 ± 0.12 -0.19 ± 0.16 0.203 
Omega-3 index 0.18 ± 0.12 0.14  ± 0.16 0.777 
1
 E4-, E2/E2, E2/E3 and E3/E3; E4+, E3/E4 and E4/E4; %TE, % total energy; data are mean change ± SEM (m6 - m0)  
2
 Data were analysed by GLM with adjustment for baseline values, centre, gender, age and change in weight (m6 - m0).  
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Figure 1: Consort diagram of participants randomized into the Food4Me Proof of 
Principle Study * Total number of participants reporting one or more exclusion criteria. Parentheses 
indicate the percentage of each group who received advice to reduce SFA intake at month 0. 
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